Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Senate Health Care Cost Transparency Initiative Doesn't Mention Drug Pricing, But Likely Can't Avoid It

Executive Summary

Bipartisan effort seems more focused on increasing cost transparency for US health care services, but stakeholders still are expected to raise drug pricing issues.
Advertisement

Related Content

Gottlieb: Real Risk Of Congressional Action If Anti-Competitive Actions Continue
Drug Pricing: PhRMA Report Aims To Shift Focus To Supply Chain
Mylan CEO Takes Center Stage To Address EpiPen Pricing Scandal
EpiPen Price Story Highlights Growing Impact Of Drug Deductibles
Senate Medical Innovation Bill: Will Slow, Small And Steady Win The Race?
FDA Reform Effort In Congress Taking Expansive View

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS122624

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel